Laboratory of Oncolytic Virus Immuno-Therapeutics

The Laboratory of Oncolytic Virus Immuno-Therapeutics (LOVIT)

Dr. Antonio Marchini

© dkfz.de

The Laboratory of Oncolytic-Virus-Immuno-Therapeutics (LOVIT) is a joint research Unit between the Luxembourg Institute of Health (LIH) and the DKFZ established in 2017 to advance research on oncolytic virus immunotherapy. LOVIT is headed by Antonio Marchini and presently includes three post-docs, one PhD Student and two technical assistants working in Heidelberg and/or Luxembourg laboratories.

Contact

Dr. Antonio Marchini
The Laboratory of Oncolytic Virus Immuno-Therapeutics (LOVIT) (F011)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 6221 42 4969

Selected Publications

  • Marchini, A., Scott, E. M., and Rommelaere, J. (2016) Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses 8
  • Marchini, A., Bonifati, S., Scott, E. M., Angelova, A. L., and Rommelaere, J. (2015) Oncolytic parvoviruses: from basic virology to clinical applications. Virol J 12, 6
  • El-Andaloussi, N., Bonifati, S., Kaufmann, J. K., Mailly, L., Daeffler, L., Deryckere, F., Nettelbeck, D. M., Rommelaere, J., and Marchini, A. (2012) Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential. J Virol 86, 10418-10431
  • Li, J., Bonifati, S., Hristov, G., Marttila, T., Valmary-Degano, S., Stanzel, S., Schnolzer, M., Mougin, C., Aprahamian, M., Grekova, S. P., Raykov, Z., Rommelaere, J., and Marchini, A. (2013) Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med 5, 1537-1555
to top